Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ligand, Eli Lilly deal

Under a restructured royalty agreement, LGND has the option to make a $20 million payment

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE